VolitionRx (VNRX) Stock Surges 70% After Cancer DNA Breakthrough
18 Mar 2026 · 14:43 UTC · CoinCentral RSS Feed · Original source
Read original at CoinCentral RSS Feed →
Summary
VolitionRx (VNRX), a biotech company, announced a breakthrough in non-invasive cancer detection. The company isolated 99%+ pure circulating tumor DNA (ctDNA) from blood samples using its proprietary Capture-Seq™ method, combining physical enrichment with bioinformatics. Trial results showed detection of 49/49 cancers in one blinded cohort and 13/14 in a second. The announcement triggered a 70% stock surge in pre-market trading on March 18, 2026, reflecting investor enthusiasm for the advancement in cancer diagnostics technology.
Why it matters
VNRX operates in biotech/oncology, not blockchain or cryptocurrency. The stock surge affects healthcare investors exclusively and has no causal mechanism to influence crypto valuations. Cryptocurrency price drivers include regulatory developments, institutional adoption, macroeconomic conditions, blockchain technology advances, and digital-asset-specific sentiment. A biotech medical breakthrough does not impact any of these crypto-specific factors. The article's appearance on CoinCentral reflects editorial scope creep rather than genuine crypto significance. The source's credibility is limited here—CoinCentral specializes in cryptocurrency, not biotech sector analysis, reducing its authority on this topic. Low originality score (7/100) indicates content republishing rather than primary reporting. This is definitively off-topic news for cryptocurrency market analysis.
Expected impact
This article reports on VolitionRx (VNRX), a biotech company's cancer DNA detection breakthrough. VNRX is a traditional healthcare stock with zero direct connection to cryptocurrency markets. The announcement of improved cancer detection via circulating tumor DNA analysis is significant for biotech investors but has negligible relevance to Bitcoin, altcoins, or cryptocurrency trading. Cryptocurrency markets will experience no measurable impact, as the news targets healthcare and biotech sectors operating in a separate investment ecosystem. Any observed crypto price movements would be coincidental and unrelated to this announcement. The publication of biotech news on a crypto-focused site does not confer cryptocurrency relevance.